Engineering a single-chain immunoglobulin scaffold loaded with a latent-releasable cytotoxic pore-forming peptide

TL;DR

Researchers engineered a modified antibody that delivers a cytotoxic peptide specifically to tumors, reducing off-target effects and improving therapeutic potential.

Contribution

A novel antibody-based delivery system for a latent cytotoxic peptide activated by tumor-specific proteases is developed.

Findings

The scIgG-Pmod2-2 hybrid retained the functional properties of the original antibody.

The construct showed favorable pharmacokinetics and tumor-specific peptide activation.

The redesigned Pmod2-2 peptide was stable and compatible with antibody fusion.

Abstract

Pore-forming peptides (PFPs) hold strong anti-tumor potential but require delivery systems to ensure stability and prevent off-target effects. In this study, we develop a strategy to transport a PFP in a biologically latent, precursor-like state. Specifically, based on the therapeutic antibody atezolizumab, which targets the tumor-associated programmed death-ligand 1, we engineered a single-chain IgG (scIgG) construct with flexible linkers embedding the melittin sequence. To further enable tumor-specific activation, melittin was flanked by regions cleavable by matriptase/ST14 (MT), a protease overexpressed in carcinomas. Initial constructs failed due to cytotoxicity during expression, prompting the redesign of melittin into a variant named Pmod2-2. This peptide retained potent pore-forming ability and was compatible with IgG fusion. The resulting scIgG-Pmod2-2 hybrid preserved Fab and Fc functionalities of the atezolizumab IgG, displayed favorable pharmacokinetics and released the active peptide in response to MT. These results highlight the potential of integrating cytolytic PFPs into antibody-based therapeutics.

Antibody–cytotoxic peptide conjugate design combines favorable pharmacokinetics with a novel mechanism for selective peptide activation by tumor metalloproteases.

Figures